Microbiome
Can E. coli Nissle vesicles calm experimental colitis?
Open access · cc by · source: Europe PMC
Oral outer-membrane vesicles from probiotic E. coli Nissle 1917 reduced DSS colitis severity in mice and lowered inflammatory cytokines while restoring TFF-3.
Study at a glance
- Design
- Animal / in-vitro — DSS colitis in male C57BL/6J mice; 10-day EcN OMV pretreatment, 5-day 3% DSS, then recovery; oral OMVs 5 μg/day
- N
- N=24 · non-colitic n=6, colitic n=9, OMV-treated n=9 (male C57BL/6J, 7–9 weeks)
- Population
- Male C57BL/6J mice with DSS-induced colitis
- Outcome
- DAI/weight, colon oedema, histology, cytokines, and barrier marker TFF-3
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
OMVs reduced weight loss and DAI, lowered colon weight/length (oedema), improved histology (P<0.05), significantly cut IL-1β, TNF-α and IL-17 mRNA, raised IL-10, and restored TFF-3 toward non-colitic levels (ZO-1 downregulation was not reversed).
Methodology
Randomized male C57BL/6J mice to non-colitic, DSS, or DSS plus daily oral EcN OMVs (5 μg) for 20 days, with 3% DSS on days 10–15, then scored clinical disease, histology, cytokines, and barrier genes.
Limitations
Mouse DSS colitis is not human ulcerative colitis; OMVs were given as pretreatment, n is small, and human safety/efficacy of non-viable vesicles was not tested.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Non-viable probiotic vesicles can still change experimental colitis in mice.
Oral outer-membrane vesicles from E. coli Nissle 1917 reduced DSS colitis severity in mice (less weight loss/DAI and oedema, better histology), cut IL-1β/TNF-α/IL-17 mRNA, raised IL-10, and restored TFF-3, without reversing ZO-1 downregulation.
Evidence for the claim as stated.
A Himalayan lifestyle-gradient community shift and mouse OMV rescue of DSS colitis both involve gut microbes, but they do not test the same host, exposure, or outcome as cancer MR or pediatric T1D timing studies.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
A Himalayan lifestyle-gradient community shift and mouse OMV rescue of DSS colitis both involve gut microbes, but they do not test the same host, exposure, or outcome as cancer MR or pediatric T1D timing studies.
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as supporting evidence on Microbiome
Oral outer-membrane vesicles from E. coli Nissle 1917 reduced DSS colitis severity in mice (less weight loss/DAI and oedema, better histology), cut IL-1β/TNF-α/IL-17 mRNA, raised IL-10, and restored TFF-3, without reversing ZO-1 downregulation.
Placed as supporting evidence on Microbiome
A Himalayan lifestyle-gradient community shift and mouse OMV rescue of DSS colitis both involve gut microbes, but they do not test the same host, exposure, or outcome as cancer MR or pediatric T1D timing studies.
Related papers in this topic
Same topic cluster — not a recommendation engine.